FeesSafety
Pluang+

Hensoldt downgraded to Buy with 43% upside amid strong execution but cautious valuation.

Analyst Insights
19 Nov 2026, 02:20 WIB
Seeking Alpha
View Source
Bullish
Hensoldt downgraded to Buy with 43% upside amid strong execution but cautious valuation.

Hensoldt (HAGHY) has been downgraded to a Buy rating due to strong operational execution but tempered by lower aerospace and defense sector trading multiples. The company’s €10.4 billion backlog and diverse product pipeline in radar, electronic warfare, and optronics support growth prospects. Hensoldt raised its 2026 revenue guidance to €2.8 billion with a target adjusted EBITDA margin of 19%, though Q4 delivery and cash conversion remain key focus areas. Despite a 15% share price decline amid broader market weakness, the stock still offers a 43% upside to the $123.60 target price. The delay of the second PEGASUS order to Q1 2027 does not significantly affect cash conversion expectations.

Hensoldt's stock is down 15% despite strong business growth projections. For readers following Industrials-sector US stocks on Pluang, here is the market snapshot as of Nov 19, 2026 05:12 WIB: out of 135 stocks, 55 rose and 79 fell. Notable movers include Enovix Corporation (ENVX) at USD 1.47 with a 7.30% gain and 100% buy order activity, Modine Manufacturing Company (MOD) at USD 138.00 up 6.37% with balanced buy/sell orders, and FuelCell Energy Inc (FCEL) at USD 7.75 down 6.00% with 79% sell orders. Typical hold times range from 11 to 49 days.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App